ADUS trades 3.6% below Wall Street's consensus target of $128.75.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ADUS achieves its forward estimates and maintains a stable P/E multiple of 17.6x. This scenario reflects the blended consensus of 18 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Addus HomeCare Corporation (ADUS) has a Wall Street consensus price target of $128.75, based on estimates from 18 covering analysts. With the stock currently trading at $124.31, this represents a potential upside of +3.6%. The company has a market capitalization of $2.32B.
Analyst price targets range from a low of $96.00 to a high of $148.00, representing a 40% spread in expectations. The median target of $135.50 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ADUS trades at a trailing P/E of 20.8x and forward P/E of 17.6x. The forward PEG ratio of 0.87 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +17.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $137.56, with bear and bull scenarios of $86.66 and $181.24 respectively. Model confidence stands at 58/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HCSGHealthcare Services Group, Inc. | $1.7B | $24.28 | $27.33 | +12.6% | Hold | 18.2x | 15 |
 ENSGThe Ensign Group, Inc. | $10.6B | $181.08 | $223.25 | +23.3% | Buy | 22.7x | 13 |
 SGRYSurgery Partners, Inc. | $3.0B | $23.20 | $23.50 | +1.3% | Buy | 65.4x | 23 |
 ALHCAlignment Healthcare, Inc. | $1.5B | $7.34 | $12.29 | +67.4% | Buy | — | 16 |
 PNTGThe Pennant Group, Inc. | $1.3B | $36.36 | $45.50 | +25.1% | Buy | 25.9x | 7 |
 UNHUnitedHealth Group Incorporated | $357.9B | $394.15 | $478.68 | +21.4% | Buy | 19.1x | 52 |
 CVSCVS Health Corp. | $107.0B | $83.85 | $109.89 | +31.1% | Buy | 10.4x | 41 |
 HUMHumana Inc. | $52.1B | $433.74 | $470.42 | +8.5% | Hold | 47.4x | 44 |
 CNCCentene Corp. | $34.5B | $69.74 | $75.43 | +8.2% | Buy | 13.2x | 44 |
 MOHMolina Healthcare, Inc. | $10.9B | $208.99 | $216.73 | +3.7% | Buy | 39.7x | 39 |
Quick answers to the most common questions about buying ADUS stock.
The consensus price target for ADUS is $128.75, close to the current price of $124.31 (3.6% implied move). Based on 18 analyst estimates, the stock appears fairly valued near current levels.
ADUS has a consensus rating of "Buy" based on 18 Wall Street analysts. The rating breakdown is predominantly bullish, with 15 Buy/Strong Buy ratings. The consensus 12-month price target of $128.75 implies 3.6% upside from current levels.
With a forward P/E of 17.6309x, ADUS trades at a relatively low valuation. The consensus target of $128.75 implies 3.6% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $148 for ADUS, while the most conservative target is $96. The consensus of $128.75 represents the median expectation. Our quantitative valuation model projects a bull case target of $181 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
ADUS is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 2 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ADUS stock forecast based on 18 Wall Street analysts shows a consensus price target of $128.75, with estimates ranging from $96 (bear case) to $148 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $138, with bear/bull scenarios of $87/$181.
Our quantitative valuation model calculates ADUS's fair value at $138 (base case), with a bear case of $87 and bull case of $181. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 58/100.
ADUS trades at a forward P/E ratio of 17.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 20.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
ADUS appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $128.75 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ADUS analyst price targets range from $96 to $148, a 40% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $128.75 consensus represents the middle ground. Our model's $87-$181 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.